SPY402.08+0.36 0.09%
DIA324.14+1.91 0.59%
IXIC11,737.08-67.92 -0.58%

ResMed's Q3 Earnings Short Of Expectations, Profit Margins Contract

Benzinga · 04/29/2022 07:50
  • ResMed Inc's (NYSE:RMDQ3 FY22 sales increased by 12% Y/Y (+14% on a constant currency basis) to $864.5 million, missing the consensus of $897 million.
  • The revenue growth was driven by increased demand for sleep and respiratory care devices and an increased demand following an ongoing recall of rival Koninklijke Philips N.V. (NYSE:PHG) products.
  • ResMed generated $35 million - $45 million incremental device revenue due to the impact of competitors' recall.
  • The company expects to face supply chain challenges hampering its ability to increase the supply of devices. 
  • ResMed expects a total incremental device revenue opportunity for FY22 of $200 million - $250 million, down from $300 million - $350 million.
  • Speaking on the earnings conference call, Chief executive Mick Farrell said that the patient backlog for sleep apnoea machines was between 12 and 18 months. 
  • The adjusted gross margin decreased to 58.1% from 59.6%, mainly due to higher freight and manufacturing costs, partially offset by favorable product mix changes and an increase in average selling prices.
  • The adjusted EPS reached $1.32, compared to $1.30 a year ago and below the consensus of $1.42.
  • Dividend: ResMed declared a quarterly cash dividend of $0.42 per share, payable on June 16 and record date of May 12.
  • Price Action: RMD shares closed lower by 0.56% at $213.51 on Thursday.